Trial
NCT02925533
Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Mark Pomerantz, MD
Collaborators
Merck Sharp & Dohme LLC; Rainier Therapeutics
Condition
Bladder Cancer
Intervention
B-701
Why stopped
Terminated due to safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-27